CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma
Phase 1 Recruiting
24 enrolled
Low Dose Mosunetuzumab for the Treatment of Patients With Indolent B-Cell Lymphoma
Phase 2 Recruiting
20 enrolled
Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy
Phase 2 Recruiting
35 enrolled
Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases
Phase NA Recruiting
200 enrolled
A Phase II Study of Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor (CAR) Tcell Therapy, in Combination With Radiotherapy (RT) in Relapsed/Refractory Follicular Lymphoma
Phase 2 Recruiting
20 enrolled
TAB
Phase 2 Recruiting
310 enrolled
GLP-1/GCG Dual Agonist in Type 2 Diabetes With Early Dementia (LIGHT-COG Study)
Phase 3 Recruiting
420 enrolled
5HTP Regulation Of Asthma In Children
Phase 2 Recruiting
20 enrolled
Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
Phase 2 Recruiting
60 enrolled
SCARF-1
Phase 2 Recruiting
40 enrolled
CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies
Phase 1/2 Recruiting
100 enrolled
Epco, Zanu, Ritux for R/R FL or MZL
Phase 2 Recruiting
45 enrolled
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
Recruiting
30 enrolled
SELECT-CAR-NK
Phase 1/2 Recruiting
85 enrolled
Efficacy and Safety of Zanubrutinib, Rituximab, and Lenalidomide (ZR²) in Combination With Tislelizumab for Relapsed/Refractory Follicular Lymphoma
Phase 2 Recruiting
33 enrolled
A Study of Reduced Dose Radiation Therapy for People With B-Cell Lymphomas
Phase 3 Recruiting
375 enrolled
B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies
Phase 1 Recruiting
27 enrolled
Evaluation of Human Immune Responses Vaccination in Patients With Lymphoma
Recruiting
200 enrolled
Loncastuximab Tesirine in Combination With Rituximab in Patients With Relapsed or Refractory Follicular Lymphoma
Phase 2 Recruiting
100 enrolled
The PRE-VAIL Study
Phase NA Recruiting
259 enrolled
Cognitive Screening Made Easy for PCPs - Administrative Supplement
Phase NA Recruiting
100 enrolled
MosuOSSHSR
Recruiting
25 enrolled
FTT PET/CT in Pancreatic Neuroendocrine Tumors
Phase 1 Recruiting
12 enrolled
FIL_MOZART
Phase 2 Recruiting
56 enrolled
Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
Phase 1 Recruiting
20 enrolled
Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma
Phase 1 Recruiting
36 enrolled
Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone Lymphoma
Phase 2 Recruiting
52 enrolled
FIL_FOLL-BIO
Recruiting
654 enrolled
FIL_GAZEBO
Phase 3 Recruiting
190 enrolled
Phase 2 Trial of Obinutuzumab and CC-99282 for Patients With Previously Untreated High Tumor Burden Follicular Lymphoma
Phase 2 Recruiting
36 enrolled
CUB-HS2025
Recruiting
363 enrolled
PRIOR
Recruiting
462 enrolled
PWD
Phase NA Recruiting
60 enrolled
PRALISS
Phase NA Recruiting
48 enrolled
Pirtobrutinib and Mosunetuzumab for the Treatment of Relapsed/Refractory Grades 1-3A Follicular Lymphoma, PROMOTE-FL Trial
Phase 2 Recruiting
22 enrolled
REEF
Phase NA Recruiting
20 enrolled
Emapalumab Prevention of CAR-T Cell Associated Toxicities
Phase 2 Recruiting
28 enrolled
Long-term Follow-up Study of Patients Receiving CAR-T Cells
Recruiting
500 enrolled
Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
Recruiting
15,000 enrolled
Loncastuximab Tesirine for the Treatment of Relapsed or Refractory B-Cell Malignancies
Phase 2 Recruiting
40 enrolled
Q702 for the Treatment of Patients With Hematologic Malignancies
Phase 1 Recruiting
46 enrolled
Mosunetuzumab and Polatuzumab Vedotin for the Treatment of Patients With Relapsed or Refractory Grade 1-3a Follicular Lymphoma
Phase 2 Recruiting
41 enrolled
STEPPING-STONe
Phase NA Recruiting
372 enrolled
Vaccine Responses in Patient With Multiple Myeloma and Non-Hodgkin Lymphoma After CAR-T Treatment
Recruiting
45 enrolled
HYCVA
Phase NA Recruiting
50 enrolled
CO-OPIF
Phase NA Recruiting
60 enrolled
Autonomic Involvement in Patient With Cognitive Decline
Phase NA Recruiting
120 enrolled
Fixed-Duration Zanubrutinib, Bendamustine, and Obinutuzumab (ZBG) in Treatment-Naïve Advanced Stage Follicular Lymphoma
Phase NA Recruiting
15 enrolled
Interventions in Mathematics and Cognitive Skills
Phase NA Recruiting
180 enrolled
A Feasibility Trial of Tazemetostat Plus CAR T Cell Therapy in B-cell Lymphomas
Phase 1 Recruiting
15 enrolled